DHR
Danaher Corporation · Healthcare · Medical - Diagnostics & Research
Momentum-inputs (vergelijkbare managers):
breedte van houders -4.0% ·
aandelenstroom +4.8% ·
netto nieuwe posities -4.2%
· formule
Geconcentreerde accumulatie: stijgende aandelen bij minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q1 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 294.05K | $63.57M | n/a | −3 |
| Q2 2026 | 188 | +7 | 434.91M | $82.90B | +10 | −4 |
| Q1 2026 | 185 | -2 | 440.89M | $83.51B | +5 | −8 |
| Q4 2025 | 186 | -1 | 467.58M | $107.03B | +2 | −2 |
| Q3 2025 | 30 | -1 | 269.80M | $53.47B | +1 | −3 |
| Q2 2025 | 29 | +2 | 237.37M | $46.89B | +3 | −1 |
| Q1 2025 | 24 | -1 | 116.89M | $23.96B | +1 | −2 |
| Q4 2024 | 25 | +1 | 111.55M | $25.60B | +1 | n/a |
| Q3 2024 | 23 | +1 | 81.67M | $22.69B | +2 | −1 |
| Q2 2024 | 22 | n/a | 81.37M | $20.32B | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passief) | 27.46M | +0.3% | $5.64B | 0.2% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 19.59M | +3.2% | $4.02B | 0.5% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Wellington Management ✦ | 17.70M | -17.0% | $3.63B | 0.7% | ▼ Trim | 4 | SEC ↗ ×9 |
| 4 | Geode Capital Management ✦ (passief) | 13.64M | +2.1% | $2.79B | 0.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 5 | Norges Bank ✦ (passief) | 9.67M | +4.2% | $1.98B | 0.3% | ▲ Add | 4 | SEC ↗ |
| 6 | Fisher Asset Management ✦ | 4.64M | +1.2% | $950.20M | 0.4% | ▲ Add | 4 | SEC ↗ |
| 7 | Capital World Investors ✦ | 4.09M | -35.7% | $838.73M | 0.1% | ▼ Trim | 4 | SEC ↗ |
| 8 | Marshall Wace ✦ | 3.61M | +709.1% | $739.23M | 1.0% | ▲ Add | 4 | SEC ↗ ×4 |
| 9 | Point72 Asset Management ✦ | 3.16M | +134.6% | $648.53M | 1.9% | ▲ Add | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 2.64M | +349.1% | $540.38M | 0.5% | ▲ Add | 4 | SEC ↗ ×2 |
| 11 | D. E. Shaw & Co. ✦ | 2.55M | +20.6% | $522.71M | 0.7% | ▲ Add | 4 | SEC ↗ ×2 |
| 12 | Arrowstreet Capital ✦ | 2.23M | +177.5% | $457.18M | 0.4% | ▲ Add | 4 | SEC ↗ |
| 13 | Millennium Management ✦ | 1.98M | +212.0% | $404.89M | 0.4% | ▲ Add | 4 | SEC ↗ |
| 14 | Two Sigma Investments ✦ | 1.11M | +7.6% | $226.65M | 0.5% | ▲ Add | 3 | SEC ↗ |
| 15 | Adage Capital Partners ✦ | 981.43K | +124.4% | $201.19M | 0.4% | ▲ Add | 4 | SEC ↗ |
| 16 | AQR Capital Management ✦ | 747.39K | +98.3% | $150.43M | 0.2% | ▲ Add | 4 | SEC ↗ ×6 |
| 17 | Viking Global Investors ✦ | 451.52K | Nieuw | $92.56M | 0.3% | New | 1 | SEC ↗ |
| 18 | Gates Foundation Trust ✦ | 373.00K | 0.0% | $76.47M | 0.2% | Held | 4 | SEC ↗ |
| 19 | PRIMECAP Management ✦ | 121.00K | +875.7% | $24.81M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 20 | Gotham Asset Management ✦ | 73.60K | +29.0% | $15.09M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 21 | Soros Fund Management ✦ | 40.00K | -69.3% | $8.20M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 22 | Dodge & Cox ✦ | 16.52K | 0.0% | $3.39M | 0.0% | Held | 4 | SEC ↗ |
| 23 | Harris Associates (Oakmark) ✦ | 15.62K | -11.6% | $3.20M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 24 | GAMCO Investors ✦ | 1.61K | -38.6% | $330,050 | 0.0% | ▼ Trim | 4 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Viking Global Investors | $92.56M | 0.3% |
Verlaten
| Third Point | $436.14M | was 5.9% |
| Bridgewater Associates | $287,856 | was 0.0% |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 2,147 houders, 548.39M aandelen, $97.77B gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer, Director · 11.31K aand · $2.46M
Officer, Director · 39.19K aand · $8.57M
Officer, Director · 7.75K aand · $1.70M
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie